Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data SeaStar Medical Holding Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0.14
1.23
Cost of revenue
0
0
0.05
Gross profit
0
0.14
1.18
Research and development
2.77
2.5
5.97
9.11
7.52
General and administrative
1.68
6.92
8.24
8.87
5.84
Operating expenses
4.45
11.6
14.2
18
13.4
Operating income
-4.45
-11.6
-14.2
-17.8
-12.2
Interest expense
0.21
0.63
1.08
0.24
0.03
Interest income
0.01
0
0.1
0.33
Other non-operating income
-0.15
-0.58
-12
-6.99
0.03
Pre-tax income
-4.6
-12.2
-26.2
-24.8
-12.1
Income tax
-0
0
0
0
0
Net income
-4.6
-12.2
-26.2
-24.8
-12.2
EPS, basic
-83.32
-370.29
-302.74
-663.60
-5.86
EPS, diluted
-83.32
-370.29
-302.74
-66.33
-5.86
Shares, basic (weighted)
0.05
0.03
0.09
0.04
2.07
Shares, diluted (weighted)
0.05
0.03
0.09
0.37
2.07
Balance sheet
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.05
0.05
0.18
1.82
12
Receivables
0
0.11
0.24
Inventory
0
0.07
Other current assets
0.03
1.46
2.13
1.84
1.3
Total current assets
0.6
1.52
2.31
3.77
13.6
Other non-current assets
0.89
0.58
Total assets
0.6
3.04
3.51
4.66
14.2
Accounts payable
0.09
1.93
4.37
3.05
0.95
Accrued liabilities
0.19
2.25
1.52
3.19
2.27
Deferred revenue
0.1
0
Short-term debt
1.18
0.57
0.57
Total current liabilities
3.12
16.1
13
6.84
3.74
Long-term debt
0
7.65
4.14
0
0
Total liabilities
3.42
23.8
17.4
6.84
3.74
Total debt
7.65
4.14
0.57
Paid-in capital
73.5
67.7
101
137
162
Retained earnings
-76.3
-88.5
-115
-140
-152
Shareholders' equity
-2.82
-20.8
-13.9
-2.18
10.4
Total equity
-2.82
-20.8
-13.9
-2.18
10.4
Total liabilities and equity
0.6
3.04
3.51
4.66
14.2
Shares outstanding
0.05
0.2
0.07
3.84
Cash flow statement
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-4.6
-12.2
-26.2
-24.8
-12.2
Stock-based compensation
0.01
1.31
1.93
0.89
0.62
Change in receivables
0
-0.11
-0.13
Change in inventory
0.06
0
0
-0.07
Change in payables
-0.3
1.55
2.45
-1.28
-2.1
Cash from operations
-5.11
-7.79
-10.3
-16
-13.6
Cash from investing
-106
Debt issued
1.09
Stock issued
0
4.74
17.4
16.1
Cash from financing
2.82
7.33
10.4
17.7
23.8
Net change in cash
-2.3
-0.46
0.13
1.64
10.2
Interest paid
0
0.01
1.13
0.55
0
Income taxes paid
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.99 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
92.6%
Gross profit / revenue.
Operating margin
-816.8%
Operating income / revenue.
Pre-tax margin
-795.3%
Pre-tax income / revenue.
Net margin
-795.5%
Net income / revenue.
Operating cash flow margin
-799.4%
Cash from operations / revenue.
Return on equity (ROE)
-317.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-157.6%
Net income / average total assets.
R&D / revenue
520.4%
Research and development expense / revenue.
Stock-based pay / revenue
20.5%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
814.1%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
774.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
204.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
67.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
454.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
298.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.89x
Current assets / current liabilities.
Quick ratio
1.65x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.60x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$3.34
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.42
Revenue / diluted weighted shares.
Operating cash flow per share
-$3.35
Cash from operations / diluted weighted shares.
Book value per share
$1.01
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
5.12x
Market cap / revenue.
P/B
2.04x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.04x
Market cap / tangible book value, when positive.
EV/Sales
1.06x
Enterprise value / revenue.
Earnings yield
-155.4%
Net income / market cap (the inverse of P/E).
What was SeaStar Medical Holding Corp's revenue in fiscal 2025?
SeaStar Medical Holding Corp reported revenue of $1.2M for fiscal 2025, 814.1% higher than the year before.
Was SeaStar Medical Holding Corp profitable in fiscal 2025?
No. It reported a net loss of $12.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.